[The role of testosterone drugs in combined therapy of erectile dysfunction in patients with metabolic syndrome].

The aim of the trial was assessment of efficacy of combined therapy with testosterone drug (androgel) and wardenafil in patients with erectile dysfunction (ED) and metabolic syndrome (MS). The trial included 16 males with organic ED, laboratory and clinical symptoms of hypogonadism and MS (mean age 63.8 +/- 8.4) who had failed monotherapy with phosphodiesterase of type 5 (FDE-5). Both routine methods and special methods of ED and MS diagnosis with application of International Index of Erectile Function were used in examination. MS was diagnosed according to the criteria of the National Cholesterol Educational Program. Wardenafil was given in a dose 20 mg 1 hour before coitus, but not less than 4 tablets a month. Androgel applications were given in a daily dose 50 mg. The treatment lasted for 3 months. The combined treatment significantly reduced body mass index, waist circumference, improved erectile function and libido. Erectile function normalized in 3 (18.75%) patients. Carbohydrate and lipid metabolism improved, the levels of total and free testosterone normalized. Elevation of sexual hormones concentration eliminated clinical hypogonadism symptoms in 68.75% patients. Thus, combined treatment with FDE-5 inhibitor wardenafil and testosterone drug androgel is effective, safe, improves erectile function, hormonal, lipid and carbohydrate blood profile and can be used in patients with MS, ED and hypogonadism.